Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$4.08 USD
-0.11 (-2.51%)
Updated May 28, 2024 04:00 PM ET
After-Market: $4.08 +0.01 (0.12%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Rapt Therapeutics [RAPT]
Reports for Purchase
Showing records 21 - 40 ( 74 total )
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
New Biomarker Data for RPT193 Further Hints at Similar Efficacy to DUPI
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
4Q2021 Update - Key Data Readout and Study Initiations Planned for 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
2021 Financial Results; AD Data Upcoming in 1H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
3Q2021 Update - RPT193 Program Advances and FLX475 Data Expected in 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Data Presentation Bodes Well for Future Advancement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Several Key Upcoming Milestones Outlined in Updated Corporate Deck
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
2Q21 Financial Results; Solid Balance Sheet; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
2Q2021 Update - Lead CCR4 Programs FLX475 and RPT193 Actively Progressing
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Clinical Data Impresses; Cash Replenished; Raising PT to $56
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Impresses in Phase 1b Atopic Dermatitis Study, Raising PT to $72
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21 Financials Reported; Modulating PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R